These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16364640)

  • 21. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
    Huang S; Li R; Connolly PJ; Xu G; Gaul MD; Emanuel SL; Lamontagne KR; Greenberger LM
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6063-6. PubMed ID: 16979339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel taspine derivatives as antiangiogenic agents.
    Zhang J; Zhang Y; Zhang S; Wang S; He L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):718-21. PubMed ID: 20006929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
    Miyazaki Y; Matsunaga S; Tang J; Maeda Y; Nakano M; Philippe RJ; Shibahara M; Liu W; Sato H; Wang L; Nolte RT
    Bioorg Med Chem Lett; 2005 May; 15(9):2203-7. PubMed ID: 15837294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
    Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
    J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    Du J; Lei B; Qin J; Liu H; Yao X
    J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
    Yang Y; Shi L; Zhou Y; Li HQ; Zhu ZW; Zhu HL
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6653-6. PubMed ID: 20943391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.
    Gaudette F; Raeppel S; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Macleod AR; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2010 Feb; 20(3):848-52. PubMed ID: 20071170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
    Luan X; Gao C; Zhang N; Chen Y; Sun Q; Tan C; Liu H; Jin Y; Jiang Y
    Bioorg Med Chem; 2011 Jun; 19(11):3312-9. PubMed ID: 21576023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent vascular endothelial growth factor receptor-2 inhibitors.
    Papakyriakou A; Katsarou ME; Belimezi M; Karpusas M; Vourloumis D
    ChemMedChem; 2010 Jan; 5(1):118-29. PubMed ID: 19921722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
    Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
    J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
    Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
    Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
    J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.